Cargando…
Development of Novel Immunotherapies for Multiple Myeloma
Multiple myeloma (MM) is a disorder of terminally differentiated plasma cells characterized by clonal expansion in the bone marrow (BM). It is the second-most common hematologic malignancy. Despite significant advances in therapeutic strategies, MM remains a predominantly incurable disease emphasizi...
Autores principales: | Al-Hujaily, Ensaf M., Oldham, Robyn A. A., Hari, Parameswaran, Medin, Jeffrey A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5037783/ https://www.ncbi.nlm.nih.gov/pubmed/27618026 http://dx.doi.org/10.3390/ijms17091506 |
Ejemplares similares
-
Discovery and validation of surface N-glycoproteins in MM cell lines and patient samples uncovers immunotherapy targets
por: Oldham, Robyn A A, et al.
Publicado: (2020) -
Recent advances in understanding multiple myeloma
por: Dhakal, Binod, et al.
Publicado: (2016) -
Recruiting Immunity for the Fight against Colorectal Cancer: Current Status and Challenges
por: Al-Hujaily, Ensaf M., et al.
Publicado: (2022) -
Risk of infections with B-cell maturation antigen-directed immunotherapy in multiple myeloma
por: Mohan, Meera, et al.
Publicado: (2022) -
Immunotherapy for Multiple Myeloma
por: Tamura, Hideto, et al.
Publicado: (2019)